BACKGROUND: The tocopherol-based oil-in-water emulsion adjuvant system family (AS03) improves antigen sparing with split-virion H5N1 influenza vaccines, representing an important development for pandemic preparedness. In this phase 1/2 randomized, controlled, observer-blinded study in 680 adults, we assessed the immunogenicity and safety of A/Indonesia/5/05 H5N1 (IBCDC-RG2, clade 2.1) prepandemic candidate vaccines produced at 2 separate manufacturing sites. METHODS: Two doses, each of which contained 3.75 microg of hemagglutinin antigen, were given 21 days apart either without adjuvant or with an adjuvant system containing 11.86 mg or 5.93 mg of tocopherol (AS03). RESULTS: The AS03-adjuvanted A/Indonesia/05/2005 (NIBRG-14) vaccines were significantly more immunogenic than nonadjuvanted vaccine in homologous assays. Neutralizing cross-clade immunogenicity against clades 1, 2.2, and 2.3 was demonstrated at day 42 with all vaccines; at 6 months, seroconversion rates were highest for clade 2.2 (60.7%) and for clade 1 (38.3%). Adjuvantation was associated with increased short-term injection-site reactions (pain) in 80% of participants, with such reactions assessed as being of grade 3 severity for 4.0% of doses. No other safety or reactogenicity concerns were identified over 6 months of follow-up. CONCLUSIONS: Humoral responses against the adjuvanted 3.75-microg hemagglutinin antigen vaccines from both manufacturing sites fulfilled European and US licensure criteria for immunogenicity for influenza vaccines.
RCT Entities:
BACKGROUND: The tocopherol-based oil-in-water emulsion adjuvant system family (AS03) improves antigen sparing with split-virion H5N1 influenza vaccines, representing an important development for pandemic preparedness. In this phase 1/2 randomized, controlled, observer-blinded study in 680 adults, we assessed the immunogenicity and safety of A/Indonesia/5/05 H5N1 (IBCDC-RG2, clade 2.1) prepandemic candidate vaccines produced at 2 separate manufacturing sites. METHODS: Two doses, each of which contained 3.75 microg of hemagglutinin antigen, were given 21 days apart either without adjuvant or with an adjuvant system containing 11.86 mg or 5.93 mg of tocopherol (AS03). RESULTS: The AS03-adjuvanted A/Indonesia/05/2005 (NIBRG-14) vaccines were significantly more immunogenic than nonadjuvanted vaccine in homologous assays. Neutralizing cross-clade immunogenicity against clades 1, 2.2, and 2.3 was demonstrated at day 42 with all vaccines; at 6 months, seroconversion rates were highest for clade 2.2 (60.7%) and for clade 1 (38.3%). Adjuvantation was associated with increased short-term injection-site reactions (pain) in 80% of participants, with such reactions assessed as being of grade 3 severity for 4.0% of doses. No other safety or reactogenicity concerns were identified over 6 months of follow-up. CONCLUSIONS: Humoral responses against the adjuvanted 3.75-microg hemagglutinin antigen vaccines from both manufacturing sites fulfilled European and US licensure criteria for immunogenicity for influenza vaccines.
Authors: Leigh M Howard; Johannes B Goll; Travis L Jensen; Kristen L Hoek; Nripesh Prasad; Casey E Gelber; Shawn E Levy; Sebastian Joyce; Andrew J Link; C Buddy Creech; Kathryn M Edwards Journal: J Infect Dis Date: 2019-05-05 Impact factor: 5.226
Authors: Allison C Galassie; Johannes B Goll; Parimal Samir; Travis L Jensen; Kristen L Hoek; Leigh M Howard; Tara M Allos; Xinnan Niu; Laura E Gordy; C Buddy Creech; Heather Hill; Sebastian Joyce; Kathryn M Edwards; Andrew J Link Journal: Proteomics Date: 2017-06 Impact factor: 3.984
Authors: Maikel V W van der Velden; Alexander Geisberger; Thomas Dvorak; Daniel Portsmouth; Richard Fritz; Brian A Crowe; Wolfgang Herr; Eva Distler; Eva M Wagner; Markus Zeitlinger; Robert Sauermann; Christoph Stephan; Hartmut J Ehrlich; P Noel Barrett; Gerald Aichinger Journal: Clin Vaccine Immunol Date: 2014-04-16
Authors: Robert L Atmar; Wendy A Keitel; John M Quarles; Thomas R Cate; Shital M Patel; Diane Nino; Janet Wells; Nancy Arden; Kuo Guo; Heather Hill; Robert B Couch Journal: Vaccine Date: 2011-08-22 Impact factor: 3.641
Authors: Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Bradley Fox; Sofia Scholar; Jeffrey Rosen; Nahida Chakhtoura; Marie Lebacq; Robbert van der Most; Philippe Moris; Sandra L Giannini; Anne Schuind; Sanjoy K Datta; Dominique Descamps Journal: Hum Vaccin Date: 2011-12-01